Page 550 - Read Online

Boortalary et al. Hepatoma Res 2020;6:48 I http://dx.doi.org/10.20517/2394-5079.2020.38 Page 7 of 7

17. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic
hepatitis C. J Hepatol 2013;59:696-700.
18. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, et al. Occult and previous hepatitis B virus infection are not associated with
hepatocellular carcinoma in united states patients with chronic hepatitis C. Hepatology 2011;54:434-42.
19. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002;2:479-86.
20. Lindh M, Hannoun C, Malmstrom S, Lindberg J, Norkrans G. Lamivudine resistance of hepatitis B virus masked by coemergence of
mutations in probe region of the cobas amplicor assay. J Clin Microbiol 2006;44:2587-9.
21. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV
infection and hepatocellular carcinoma. Liver Int 2015;35:2311-7.
22. Wong DK, Cheng SCY, Mak LL, To EW, Lo RC, et al. Among patients with undetectable hepatitis B surface antigen and hepatocellular
carcinoma, a high proportion has integration of HBV DNA into hepatocyte DNA and no cirrhosis. Clin Gastroenterol Hepatol
2020;18:449-56.
23. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of
hepatocellular carcinoma cells to select t cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.
24. Yip TC, Chan HL, Wong VW, Tse YK, Lam KL, et al. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B
surface antigen seroclearance. J Hepatol 2017;67:902-8.
25. Ahn SH, Park YN, Park JY, Chang HY, Lee JM, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis
B surface antigen seroclearance. J Hepatol 2005;42:188-94.
26. Yuen MF, Wong DK, Fung J, Ip P, But D, et al. Hbsag seroclearance in chronic hepatitis B in asian patients: Replicative level and risk of
hepatocellular carcinoma. Gastroenterology 2008;135:1192-9.
27. Koga H, Kai K, Aishima S, Kawaguchi A, Yamaji K, et al. Occult hepatitis B virus infection and surgical outcomes in non-B, non-C
patients with curative resection for hepatocellular carcinoma. World J Hepatol 2017;9:1286-95.
28. Hann HW, Bergin D, Coben R, DiMarino AJ. Prevention of new hepatocellular carcinoma with concomitant antiviral therapy in chronic
hepatitis B patients whose initial tumor was successfully ablated. Int J Cancer 2011;128:739-42.
29. Hann HW, Coben R, Brown D, Needleman L, Rosato E, et al. A long-term study of the effects of antiviral therapy on survival of patients
with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation. Cancer Med 2014;3:390-6.
30. Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular
carcinoma: an updated meta-analysis. Can J Gastroenterol Hepatol 2016;2016:5234969.